Physician profile
John Rahhal
NPI 1164490223
$696.30
in general payments reported to CMS, 2019-2025
16 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $242 · 2024: $186 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.30 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $95.28 | 2023-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $57.22 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $45.01 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $37.53 | 2025 | Secuado, Xelstrym |
| Otsuka America Pharmaceutical, INC. | $32.64 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $28.45 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $25.01 | 2025 | Aristada, Lybalvi |
| Sage Therapeutics, LLC | $24.70 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $23.18 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $20.15 | 2023 | Qelbree |
| Tris Pharma INC | $18.54 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.02 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $15.68 | 2024 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $14.37 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rahhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.